Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Skye Bioscience Inc (OP: SKYE ) N/A UNCHANGED Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Skye Bioscience Inc < Previous 1 2 3 Next > Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants December 22, 2022 This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). Via Benzinga Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE December 20, 2022 San Diego, California--(Newsfile Corp. - December 20, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Exposures Product Safety Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down December 19, 2022 MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January. Via Benzinga Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion December 16, 2022 San Diego, California--(Newsfile Corp. - December 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids April 08, 2021 Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this artic... Via Benzinga Topics Cannabis Exposures Cannabis Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer December 13, 2022 San Diego, California--(Newsfile Corp. - December 13, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Derivatives Intellectual Property Exposures Derivatives Intellectual Property Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference November 22, 2022 San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA November 17, 2022 San Diego, California--(Newsfile Corp. - November 17, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Derivatives Exposures Derivatives Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma November 16, 2022 Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial... Via Benzinga Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100 November 16, 2022 - Recruitment for cohort 1 has begun- ... Via Newsfile Skye Bioscience Closes Acquisition of Emerald Health Therapeutics November 10, 2022 San Diego, California--(Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Cannabis Exposures Cannabis Product Safety Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc. September 30, 2022 San Diego, California--(Newsfile Corp. - September 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Derivatives Exposures Derivatives Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma September 20, 2022 Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has... Via Benzinga Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience August 26, 2022 Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company")... Via Newsfile Emerald Health Therapeutics Shareholders Vote in Favour of Plan of Arrangement with Skye Bioscience August 19, 2022 Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the... Via Newsfile Topics Regulatory Compliance Exposures Legal Regulatory Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma July 25, 2022 Modern cannabis research reportedly began with Israeli scientists Raphael Mechoulam and Yechiel Gaoni who, in 1964, isolated and identified tetrahydrocannabinol (THC). Mechoulam later also elucidated... Via Benzinga Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer July 21, 2022 Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing... Via Benzinga Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion June 30, 2022 San Diego, California--(Newsfile Corp. - June 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details May 12, 2022 Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc. Via Benzinga Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience May 12, 2022 Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to... Via Newsfile Topics Derivatives Exposures Derivatives Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma March 03, 2022 Skye Bioscience, Inc. (OTCQB:SKYE) has entered into... Via Benzinga Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics December 23, 2021 Skye Bioscience Announces Board Additions & Promotions CBD-focused biopharmaceutical company Skye Bioscience, Inc. Via Benzinga These OTC Securities Had the Most Trading Activity in June July 20, 2021 Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... Via Benzinga Topics Cannabis Exposures Cannabis Watch CV Sciences & Lyphe Group On The Benzinga Cannabis Hour July 08, 2021 Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane... Via Benzinga Topics Cannabis Exposures Cannabis CEO Presenting on the Emerging Growth Conference on June 9. Register here June 07, 2021 Niche Companies in Technology, Biotech, Precious Metals, and more in Attendance Via EIN Presswire Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021 April 19, 2021 LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be... From Stock News Now Via AccessWire Topics Cannabis Exposures Cannabis < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.